Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-04-17
2008-09-23
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S523000
Reexamination Certificate
active
07427611
ABSTRACT:
Compounds having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity corresponding to the formula I,wherein the substituents R1, R2, R3and R4have the meanings given in the description and also pharmaceutical compositions containing these compounds, in particular pharmaceutical compositions suitable for treating or inhibiting cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
REFERENCES:
patent: 5677297 (1997-10-01), Waldeck et al.
patent: 5952327 (1999-09-01), Waldeck et al.
patent: 2003/0045449 (2003-03-01), Lowe, III et al.
patent: 0 733 642 (1996-09-01), None
patent: 0 830 863 (1998-03-01), None
patent: 1 097 719 (2001-05-01), None
patent: WO 99/55726 (1999-11-01), None
patent: WO 00/48601 (2000-08-01), None
patent: WO 01/03699 (2001-01-01), None
patent: WO 01/36610 (2001-05-01), None
patent: WO 02/06492 (2002-01-01), None
patent: WO 02/079143 (2002-10-01), None
patent: WO 02/094176 (2002-11-01), None
Alexandru E. Benet, M.D., et al., Male Erectile Dysfunction Assessment and Treatment Options, Comprehensive Therapy 1994; 20 (12):669-673, Bronx, New York.
SR Leiblum, Definition and classification of female sexual disorders, International Journal of Impotence Research (1998), 10, Suppl. 2, S104-S106, Piscataway, NJ.
Arnold Melman et al., The Epidemiology and Pathophysiology of Erectile Dysfunction, The Journal of Urology, vol. 161, pp. 5-11, Jan. 1999, United Kingdom.
K. Park et al., Vasculogenic female sexual dysfunction: The hemodynamic basis for vaginal engorgement insufficiency and clitoral erectile insufficiency, International Journal of Impotence Research, (1997) 9, pp. 27-37, Boston, MA.
Makoto Sumitomo et al., Chemosensitization of Androgen-Independent Prostate Cancer with Neutral Endopeptidase, vol. 10, pp. 260-266, Jan. 1, 2004, New York, NY.
Herbert M. User et al., Microarray Analysis and Description of SMR1 Gene in Rat Penis in a Post-Radical Prostatectomy Model of Erectile Dysfunction, The Journal of Urology, vol. 170, pp. 298-801, Jul. 2003, Chicago, Illinois.
Jennifer R. Berman et al., Female sexual dysfunction: anatomy, physiology, evaluation and treatment options; Current Opinion in Urology, 1999, 9:563-568, Boston, MA.
I. Goldstein et al., Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes, International Journal of Impotence Research (1998) 10, Suppl. 2, S84-S90, Boston, MA.
A.M. Naylor, Endogenous neurotransmitters mediating penile erection, British Journal of Urology (1998), 81, pp. 424-431, Sandwich, UK.
Reza Tabrizchi, SLV-306 Solvay, Current Opinion in Investigational Drugs, 2003, vol. 4, No. (3), 329-332, Canada.
Harvey C. Taub, M.D. et al., Relationship Between Contraction and Relaxation in Human and Rabbit Corpus Cavernosum, Adult Urology, Dec. 1993, vol. 42, No. 6, pp. 698-704, Bronx, New York.
Keiji Kubo et al., Nonpeptide Angiotensin II Receptor Antagonists. Synthesis and Biological Activity of Potential Prodrugs of Benzimidazole-7-carboxylic Acids, J. Med. Chem. 1998, 36, pp. 2343-2349, Osaka, Japan.
Luis M. Cruz-Orive et al., Recent stereological methods for cell biology: a brief survey, Am. J. Physiol. 258 (Lung Cell. Mol. Physiol. 2): L148-L156, 1990, Switzerland.
R. J. Levin, VIP, Vagina, Clitoral and Perurethral Glans—an Update on Human Female Genital Arousal, Exp. Clin. Endocrinol., vol. 98, No. 2, 1991, pp. 61-69, Great Britain.
JAMA, Impotence, NIH Consensus Conference, Jul. 7, 1993, vol. 270, No. 1, pp. 83-90, Bethesda, MD.
F. W. Sum et al., Prodrugs of CL316243: A Selective β3-Adrenergic Receptor Agonist for Treating Obesity and Diabetes, Bioorganic & Medicinal Chemistry Letters 9 (1999) pp. 1921-1926, Pearl River, NY.
Yoshinobu Yoshimura et al., Preparation of 1-Acyloxyethyl Esters of 7-[2-(2-Aminothiazol-4-YL)Acetamidol]-3-[[[ 1-(2-Dimethylaminoethyl)-1H-Tetrazol-5-YL]Thio]-Methyl]Ceph-3-EM-4-Carboxylic Acid (Cefotiam) and Their Oral Absorption In Mice, The Journal of Antibiotics, vol. XXXIX No. 9, pp. 1329-1342, Osaka, Japan (1986).
Fischer Yvan
Hoefer Constanze
Hoeltje Dagmar
Ikonomidou Hrissanthi
Karimi-Nejad Yasmin
Crowell & Moring LLP
Kifle Bruck
Solvay Pharmaceuticals GmbH
LandOfFree
Amidomethyl-substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amidomethyl-substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amidomethyl-substituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3987175